scholarly journals GTPase Ral—a new tumour target

2014 ◽  
Vol 11 (12) ◽  
pp. 658-658 ◽  
Author(s):  
Clemens Thoma
Keyword(s):  
1995 ◽  
Vol 20 (4) ◽  
pp. 515-523
Author(s):  
A. Sarin ◽  
Q. B. Saxena ◽  
R. B. Herberman ◽  
R. K. Saxena

Mutagenesis ◽  
2020 ◽  
Author(s):  
Melissa Badding ◽  
B Bhaskar Gollapudi ◽  
Sean Gehen ◽  
Zhongyu (June) Yan

Abstract 1,3-Dichloropropene (1,3-D; CAS No. 542-75-6) is a soil fumigant used for the control of nematodes in agriculture. There is an extensive database on the genotoxicity of 1,3-D and many of the published studies are confounded by the presence of mutagenic stabilisers in the test substance. Mixed results were obtained in the in vitro assays, often due to the purity of the 1,3-D sample tested. In order to get further clarity, the mutagenic potential of 1,3-D was investigated in vivo in the transgenic Big Blue rodent models. Inhalation exposure of 150 ppm 1,3-D (×2.5 tumourigenic dose) to transgenic male B6C3F1 mice did not induce lacI mutations in either the lung (tumour target tissue) or liver. Similarly, dietary administration of 1,3-D up to 50 mg/kg/day to transgenic male Fischer 344 rats did not increase the cII mutant frequency in either the liver (tumour target) or kidney. These results, along with other available in vivo data, including the absence of DNA adducts and clastogenic/aneugenic potential, support the conclusion that 1,3-D is efficiently detoxified in vivo and, as such, does not pose a mutagenic hazard or risk.


BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
P. B. A. A. van Driel ◽  
M. C. Boonstra ◽  
H. A. J. M. Prevoo ◽  
M. van de Giessen ◽  
T. J. A. Snoeks ◽  
...  

2012 ◽  
Vol 6 (6) ◽  
pp. 283 ◽  
Author(s):  
Uri Lindner ◽  
Sangeet Ghai ◽  
Paula Spensieri ◽  
Eugen Hlasny ◽  
Theodorus H. Van der Kwast ◽  
...  

The treatment of low-risk prostate cancer is a common clinical dilemma between standard curative whole gland therapy (and its associated quality of life diminishing side effects) and active surveillance (and its low, but real, risk of progression). The goal of focal therapy in low-risk prostate cancer is to achieve the best balance between cancer control and maintenance of quality of life. Magnetic resonance-guided focused ultrasound (MRgFUS) surgery is a non-invasive thermal ablation method that integrates magnetic resonance imaging for target identification, treatment planning and closed-loop control of thermal deposition and focused ultrasound for thermal ablation of the tumour target. This novel transrectal system allows for tumour localization, targeting and monitoring of tumour target ablation in real time, while simultaneously preserving adjacent normal tissue thereby minimizing the side effects of standard curative surgical or radiation therapy. We report the first North American clinical experience of treatment of localized prostate cancer with focal MR-guided transrectal focused ultrasound (clinicaltrial.gov identifier NCT01226576).


Sign in / Sign up

Export Citation Format

Share Document